EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency

In brief

This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).

Key facts

Study ID

NCT06525298

Run by

Eisbach Bio GmbH

People needed

144

Starts

2024-09-09

Expected to finish

2027-12-01

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Recurrent locally advanced or metastatic solid tumors
• Homologous recombination deficient mutations
• Progressed on at least on prior line of treatment or intolerant to additional effective standard therapy
• Measurable disease (RECIST 1.1 Criteria)
• Adequate organ and bone marrow function
• ECOG Performance Status 0 or 1
• Life expectancy > 3 months

You may not qualify if…

• History or evidence of any clinically relevant gastrointestinal disease
• Radiation therapy within ≤2 weeks
• Significant cardiovascular disease
• Uncontrolled, active, symptomatic brain metastases

Where it is running

• MD Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.